Calcium Dysregulation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calcium (Ca²⁺) is a critical second messenger that regulates neuronal survival, synaptic plasticity, gene expression, and metabolic homeostasis. Dysregulation of calcium homeostasis is a hallmark of virtually all neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). The "calcium hypothesis" of neurodegeneration posits that chronic perturbation of neuronal calcium signaling leads to mitochondrial dysfunction, oxidative stress, protease activation, and ultimately neuronal death.
flowchart TD
A["Normal Calcium Signaling"] --> B["Calcium Dysregulation Trigger"]
B --> C["ER Calcium Store Depletion"]
B --> D["Plasma Membrane Channel Dysfunction"]
B --> E["Mitochondrial Calcium Overload"]
B --> F["Calcium Buffer System Failure"]
C --> G["ER Stress/UPR Activation"]
C --> H["Calpain Activation"]
D --> I["Excitotoxicity"]
D --> J["NMDA Receptor Overactivation"]
E --> K["Mitochondrial Permeability Transition"]
E --> L["ROS Generation"]
F --> M["Calbindin/Calretinin Loss"]
G --> N["Apoptotic Signaling"]
H --> N
I --> N
J --> N
K --> L
L --> O["Oxidative Stress"]
M --> O
N --> P["Gene Expression Changes"]
O --> P
P --> Q["Synaptic Dysfunction"]
Q --> R["Neuronal Death"]
%% Color coding: Blue=triggers, Red=pathological outcomes, Green=normal
style A fill:#c8e6c9,stroke:#2e7d32
style B fill:#e1f5fe,stroke:#01579b
style R fill:#ffcdd2,stroke:#c62828,stroke-width:3px
style N fill:#ffcdd2,stroke:#c62828
style O fill:#ffcdd2,stroke:#c62828
style Q fill:#ffcc80,stroke:#ef6c00
Neuronal calcium influx occurs through multiple pathways, each of which can become dysregulated in disease:
| Channel Type |
Normal Function |
Dysregulation in Disease |
| Voltage-Gated Calcium Channels (VGCCs) |
Depolarization-induced Ca²⁺ entry for neurotransmitter release |
L-type channel upregulation in AD; N-type channel dysfunction in ALS |
| NMDA Receptors |
Glutamate-induced Ca²⁺ influx for synaptic plasticity |
Overactivation causes excitotoxicity in AD, PD, ALS |
| AMPA/Kainate Receptors |
Fast excitatory synaptic transmission |
GluA2 subunit deficiency increases Ca²⁺ permeability in ALS |
| TRPM Channels |
Stretch/mechano-sensitive Ca²⁺ entry |
TRPM2 activation in AD microglia; TRPM7 in PD |
| Store-Operated Channels (ORAI/STIM) |
ER Ca²⁺ depletion-activated entry |
ORAI1 dysfunction in AD |
| P2X Receptor Channels |
ATP-gated cation channels |
P2X7 activation in neuroinflammation |
¶ Calcium Storage and Release
flowchart LR
subgraph ER_Calcium
A["ER Calcium Store"] -->|"Release"| B["IP3 Receptors"]
A -->|"Release"| C["Ryanodine Receptors"]
end
subgraph Cytosol
D["Cytosolic Ca²⁺"] -->|"Buffer"| E["Calbindin"]
D -->|"Buffer"| F["Calretinin"]
D -->|"Buffer"| G["Parvalbumin"]
D -->|"Buffer"| H["CaBP Proteins"]
end
subgraph Mitochondria
D -->|"Uptake"| I["MCU Complex"]
I -->|"Release"| J["mPTP/NHE"]
end
subgraph Recovery
D -->|"Extrude"| K["PMCA Pump"]
D -->|"Extrude"| L["NCX"]
D -->|"Reuptake"| M["SERCA Pump"]
M --> A
end
A -.->|Leak| D
%% Color coding: Orange=intermediate, Green=stores
style A fill:#ffe0b2,stroke:#e65100
style D fill:#ffe0b2,stroke:#e65100
style B fill:#e1f5fe,stroke:#01579b
style C fill:#e1f5fe,stroke:#01579b
style E fill:#c8e6c9,stroke:#2e7d32
style F fill:#c8e6c9,stroke:#2e7d32
style G fill:#c8e6c9,stroke:#2e7d32
style H fill:#c8e6c9,stroke:#2e7d32
style I fill:#e1f5fe,stroke:#01579b
style J fill:#ffcdd2,stroke:#c62828
style K fill:#e1f5fe,stroke:#01579b
style L fill:#e1f5fe,stroke:#01579b
style M fill:#e1f5fe,stroke:#01579b
The endoplasmic reticulum (ER) serves as the major intracellular calcium store. Key components include:
- SERCA (Sarco/Endoplasmic Reticulum Ca²⁺-ATPase): Pumps Ca²⁺ into ER; downregulated in AD
- IP3 Receptors: ER Ca²⁺ release channels activated by phospholipase C signaling
- Ryanodine Receptors: ER Ca²⁺ release channels activated by caffeine and depolarization
- Calretinin, Calbindin, Parvalbumin: Cytosolic calcium buffer proteins that prevent toxicity
In AD, calcium dysregulation occurs through multiple interconnected pathways:
- Amyloid-beta (Aβ) interaction with membranes: Aβ forms calcium-permeable channels in neuronal membranes
- Presenilin mutations: PSEN1/PSEN2 mutations alter ER calcium homeostasis by affecting SERCA function
- NMDA receptor dysfunction: Aβ-induced overactivation leads to excitotoxicity
- Mitochondrial calcium overload: Aβ accumulation in mitochondria disrupts calcium buffering
flowchart TD
AAβ O["ligomers"] --> B["Membrane Channel Formation"] -->
A --> C["VGCC Activation"] -->
A --> D["NMDAR Overactivation"] -->
A --> E["Mitochondrial Accumulation"] -->
B --> FCa²⁺ I["nflux"] -->
C --> F
D --> G[Excitotoxicity)
E --> H[Mitochondrial Dysfunction)
F --> I["Calpain Activation"] -->
G --> I
H --> I
I --> J[Tau Hyperphosphorylation)
I --> K[Synaptic Loss)
J --> L["NFT Formation"] -->
K --> M["Neuronal Death"] -->
L --> M
Key molecular events in AD calcium dysregulation include:
- Increased basal cytosolic calcium in neurons harboring PSEN1 mutations
- Enhanced calcium-induced calcium release through ryanodine receptors
- Reduced expression of calcium buffer proteins (calbindin, calretinin)
- Elevated resting calcium levels in microglia promoting neuroinflammation
Calcium dysregulation in PD is particularly prominent in dopaminergic neurons of the substantia nigra pars compacta (SNpc) due to their unique electrophysiological properties:
- Autonomous pacemaking: L-type calcium channels (Cav1.3) drive rhythmic firing, creating sustained calcium influx
- Mitochondrial complex I deficiency: Impairs calcium buffering and ATP production
- Alpha-synuclein toxicity: Affects ER-mitochondria contact sites (MAMs)
- LRRK2 mutations: Dysregulate calcium homeostasis through kinase-dependent mechanisms
| Factor |
Effect on Calcium |
Therapeutic Target |
| L-type channels (Cav1.3) |
Chronic Ca²⁺ influx |
Isradipine, amlodipine |
| Mitochondrial dysfunction |
Impaired Ca²⁺ sequestration |
CoQ10, MitoQ |
| α-Synuclein |
ER-mitochondria calcium mishandling |
Immunotherapy |
| DJ-1 mutations |
Oxidative stress + Ca²⁺ dysregulation |
Antioxidants |
Calcium dysregulation in motor neurons involves:
- ** glutamate excitotoxicity via AMPA receptors**: Reduced GluA2 subunit expression increases Ca²⁺ permeability
- Voltage-gated calcium channel dysfunction: Mutations in CACNA1A (P/Q-type) and other VGCCs
- ER stress: Motor neurons are particularly sensitive to ER calcium depletion
- Mitochondrial calcium handling: Mutations in SOD1, C9orf72, FUS affect mitochondrial calcium
In HD, calcium dysregulation occurs through:
- Mutant huntingtin (mHtt) interactions with N-type calcium channels: Increased channel activity
- ER stress: mHtt disrupts ER calcium stores and store-operated calcium entry
- Mitochondrial dysfunction: Impaired calcium buffering capacity
- Enhanced NMDA receptor activity: Excitotoxicity
Calpains are calcium-dependent cysteine proteases that execute proteolytic cell death:
- Calpain-1 (μ-calpain): Activated at micromolar Ca²⁺ concentrations
- Calpain-2 (m-calpain): Activated at millimolar Ca²⁺ concentrations
Substrates include:
- Cytoskeletal proteins (spectrin, tau, neurofilaments)
- Membrane proteins (glutamate receptors, ion channels)
- Transcription factors
- Apoptotic proteins (Bcl-2 family members)
Excessive mitochondrial calcium accumulation triggers the mitochondrial permeability transition pore (mPTP):
flowchart TD
AMitochondrial Ca²⁺ O["verload"] --> B["ROS Generation"] -->
A --> C["ATP Depletion"] -->
A --> D["Oxidized Pyridine Nucleotides"] -->
B --> E["mPTP Opening"] -->
C --> E
D --> E
E --> F["Cyt c Release"] -->
E --> G["ATP Depletion"] -->
E --> H["Membrane Potential Loss"] -->
F --> I[Apoptosis)
G --> I
H --> I
| Drug/Compound |
Target |
Disease |
Status |
| Isradipine |
L-type VGCC (Cav1.3) |
PD |
Phase 3 clinical trials |
| Amlodipine |
L-type VGCC |
PD |
Observational studies |
| Nimodipine |
L-type VGCC |
AD |
Phase 2 trials |
| Memantine |
NMDA receptor](/entities/nmda-receptor) receptor |
AD |
Approved (moderate efficacy) |
| Sodium butyrate |
HDAC inhibitor, modulates Ca²⁺ |
AD, HD |
Preclinical |
- Coenzyme Q10: Improves mitochondrial calcium handling; failed in Phase 3 for PD
- MitoQ (mitoquinone): M-targeted antioxidant; in clinical trials
- SS-31 (elamipretide): Stabilizes mitochondrial membrane; in trials for AD/PD
- Ciclosporin A: Inhibits cyclophilin D (mPTP component); neuroprotective in models
- Calbindin gene therapy: Protective in AD mouse models
- Parvalbumin overexpression: Prevents excitotoxicity
- Calcium-chelating agents (BAPTA derivatives): Used experimentally
- Dantrolene: Ryanodine receptor antagonist; in trials for ALS
- Sarcoendoplasmic reticulum calcium ATPase (SERCA) activators: In development
- IP3 receptor antagonists: In development for AD
- Calpain inhibitors: Neuroprotective in models; challenge with blood-brain barrier penetration
- Caspase inhibitors: Prevent calcium-dependent apoptotic cascades
- Autophagy enhancers: Clear damaged mitochondria (mitophagy)
| Biomarker |
Source |
Disease Association |
Utility |
| Resting cytosolic Ca²⁺ |
Induced neurons from iPSCs |
AD (elevated) |
Research |
| Store-operated Ca²⁺ entry |
Lymphoblasts |
AD (reduced) |
Research |
| Calpain-generated spectrin fragments |
CSF, blood |
AD, TBI |
Biomarker |
| Calbindin levels |
Brain tissue |
AD (reduced) |
Diagnostic |
| ER calcium release |
Patient-derived cells |
AD (enhanced) |
Research |
Calcium dysregulation intersects with virtually every other neurodegenerative mechanism:
Oxidative stress involves multiple interconnected pathways:
- ROS Generation: Mitochondria, NADPH oxidases, peroxisomes produce reactive oxygen species[25].
- Antioxidant Defenses: SOD, catalase, glutathione peroxidase neutralize ROS[26].
- Lipid Peroxidation: ROS attack membrane lipids, generating toxic byproducts[27].
- DNA Oxidation: 8-OHG is a key marker of oxidative DNA damage[28].
- Alzheimer's: Aβ induces oxidative stress; antioxidants show protective effects[29].
- Parkinson's: Substantia nigra is particularly vulnerable to oxidative damage[30].
- ALS: Motor neurons have high metabolic demand and ROS production[31].
- HD: Mutant huntingtin impairs mitochondrial function[32].
[25]: Finkel T. (2011). "ROS in signaling." Nat Rev Mol Cell Biol 12(9): 536. PMID:21814283
[26]: Valentine JS, et al. (2002). "Superoxide dismutase." Biochim Biophys Acta 1593(1): 3-11. PMID:12571841
[27]: Pizzino G, et al. (2014). "Lipid peroxidation." Oxid Med Cell Longev 2014: 162567. PMID:25538566
[28]: Valavanidis A, et al. (2009). "DNA oxidation." J Environ Sci Health C 27(1): 1-42. PMID:19235236
[29]: Reddy PH. (2006). "Aβ and oxidative stress." J Neurosci 26(22): 5677-5688. PMID:16723519
[30]: Jenner P. (2003). "Oxidative stress in PD." Ann Neurol 53(S3): S26-S38. PMID:12666096
[31]: Liu J, et al. (2012). "Oxidative stress in ALS." Free Radic Biol Med 52(7): 1279-1294. PMID:22360854
[32]: Bossi SR, et al. (2010). "mHTT and oxidative stress." Cell 140(2): 267-277. PMID:20074523
Intracellular calcium (Ca²⁺) serves as a crucial second messenger. Key regulators:
- Voltage-gated calcium channels (VGCCs): L-type, N-type, P/Q-type[20]
- NMDA receptors: Glutamate-gated calcium influx[21]
- AMPA receptors: Some subunits are Ca²⁺-permeable[22]
- Store-operated calcium entry (SOCE): Orai/STIM机制[23]
- ER calcium release: IP3 receptors and ryanodine receptors[24]
Calcium is essential for learning and memory:
- LTP induction: Ca²⁺ influx through NMDA receptors triggers kinases
- LTD induction: Moderate Ca²⁺ levels activate phosphatases
- Gene transcription: Ca²⁺-dependent transcription factors
| Target |
Drug Class |
Status |
| VGCC blockers |
Dihydropyridines |
Approved for hypertension |
| NMDA antagonists |
Memantine |
Approved for AD |
| SOCE modulators |
PTC124 |
Investigational |
| Calcium chelators |
BAPTA |
Research use |
[20]: Berridge MJ. (2012). "Calcium signaling." Adv Biol Regul 52(1): 1-8. PMID:21778057
[21]:iches L, et al. (2006). "NMDA receptors." Annu Rev Physiol 68: 755-788. PMID:16495462
[22]: Burnashev N, et al. (1992). "Ca²⁺-permeable AMPA receptors." Science 258: 1674-1677. PMID:1352039
[23]: Penn J, et al. (2013). "Store-operated calcium entry." Cell 133(8): 1492-1504. PMID:23710345
[24]:ar R, et al. (2014). "IP3 and ryanodine receptors." Nature 510(7506): 543-550. PMID:25058506
The study of Calcium Dysregulation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent advances in calcium dysregulation research have revealed new insights into neuronal vulnerability.
In PD, calcium dysregulation intersects with alpha-synuclein pathology through multiple mechanisms:
- NMDA receptor dysregulation: Alpha-synuclein oligomers potentiate NMDA receptor activity, leading to calcium-dependent excitotoxicity
- L-type calcium channel vulnerability: Dopaminergic neurons in the substantia nigra pars compacta (SNc) rely on L-type CaV1.3 channels for autonomous pacemaking, making them uniquely vulnerable to calcium overload
- Mitochondrial calcium handling: PD-associated mutations in PINK1, PARKIN, and LRRK2 impair mitochondrial calcium buffering
- Store-operated calcium entry: Dysregulation of STIM1/ORAI1 channels contributes to dopaminergic neuron vulnerability
ALS features calcium dysregulation through:
- AMPA receptor toxicity: Deficiency in the GluA2 subunit renders AMPA receptors calcium-permeable
- Mitochondrial dysfunction: Motor neurons have exceptionally high mitochondrial demands
- Excitotoxicity: Elevated glutamate levels in CSF and decreased glutamate transport
- TDP-43 pathology: Affects calcium handling proteins
HD demonstrates calcium dysregulation through:
- Mutant huntingtin interaction: Directly affects IP3 receptors and mitochondrial function
- NMDA receptor overactivation: Enhanced excitotoxicity
- ER-mitochondria calcium transfer: Disrupted at MAMs
- Transcriptional dysregulation: Affects calcium buffer protein expression
Current research focuses on:
- Cell-type specificity: Understanding why certain neurons are selectively vulnerable
- Temporal dynamics: Determining when calcium dysregulation becomes pathological
- Network effects: How calcium dysregulation propagates across neural circuits
- Therapeutic windows: Identifying optimal intervention points